# EDGAR Filing Document

**Accession Number:** 0001267565
**File Stem:** 0001104659-25-107389
**Filing Date:** 2025-11
**Character Count:** 62743
**Document Hash:** c3f8d13d56b38e39db0d126ea2797381
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-107389.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001104659-25-107389

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 38

**CONFORMED PERIOD OF REPORT**: 20251106

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COLLEGIUM PHARMACEUTICAL, INC
- **CENTRAL INDEX KEY:** 0001267565
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** VA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37372
- **FILM NUMBER:** 251456175

**BUSINESS ADDRESS:**
- **STREET 1:** 100 TECHNOLOGY CENTER DRIVE
- **CITY:** STOUGHTON
- **STATE:** MA
- **ZIP:** 02072
- **BUSINESS PHONE:** 781-713-3699

**MAIL ADDRESS:**
- **STREET 1:** 100 TECHNOLOGY CENTER DRIVE
- **CITY:** STOUGHTON
- **STATE:** MA
- **ZIP:** 02072

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COLLEGIUM PHARMACEUTICAL INC
- **DATE OF NAME CHANGE:** 20031020

?xml version='1.0' encoding='ASCII'? COLLEGIUM PHARMACEUTICAL, INC._November 6, 2025

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 6, 2025**

**COLLEGIUM PHARMACEUTICAL, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Virginia** | **001-37372** | **03-0416362** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
|  | **100 Technology Center Drive** |  |
|  | **Suite 300** |  |
|  | **Stoughton, MA 02072** |  |
|  | (Address of principal executive offices) (Zip Code) |  |

---

Registrant's telephone number, including area code: **(781) 713-3699**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, par value $0.001 per share | COLL | The NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On November 6, 2025, Collegium Pharmaceutical, Inc. (the "Company") issued a press release announcing its financial results for the quarterly period ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 2.02 of this Current Report on Form 8-K.

**Item 7.01 Regulation FD Disclosure.**

On November 6, 2025, Collegium Pharmaceutical, Inc. released an earnings presentation. The presentation is attached hereto as Exhibit 99.2 and is being furnished, not filed, under Item 7.01 of this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | <br>**Description** |
| 99.1 | [Press Release, dated November 6, 2025](coll-20251106xex99d1.htm) |
| 99.2 | [Earnings Presentation, dated November 6, 2025](coll-20251106xex99d2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **Collegium Pharmaceutical, Inc.** | **Collegium Pharmaceutical, Inc.** |
| By: | /s/ Colleen Tupper |
|  | Colleen Tupper |
|  | Executive Vice President and Chief Financial Officer |

---

Dated: November 6, 2025

## Exhibit 99.1

**Exhibit 99.1**

![Graphic](coll-20251106xex99d1001.jpg)

**Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance**

*– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year –* 

*– Generated Record Quarterly Jornay PM*<sup>®</sup> *Net Revenue of $41.8 Million; <br>Grew Prescriptions by 20% Year-over-Year –*

*– Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year –*

*– Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million –*

*– Ended Q3'25 with Cash, Cash Equivalents and Marketable Securities of $285.9 Million –*

*– Conference Call Scheduled for Today at 8:00 a.m. ET –*

**STOUGHTON, Mass., November 6, 2025** -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter ended September 30, 2025, and provided a business update.

"We delivered another strong quarter of results driven by our portfolio of differentiated medicines and unwavering commitment to patients," said Vikram Karnani, President and Chief Executive Officer. "Jornay PM prescription growth was further bolstered by the start of the back-to-school season, as both patients and healthcare providers increasingly recognize the unique benefits of Jornay PM. The outstanding performance of Jornay PM, along with sustained growth across our pain portfolio, has led us to raise our 2025 financial guidance. As we move into the fourth quarter and look ahead to 2026, we remain dedicated to supporting patients with serious medical conditions while driving shareholder value through strong commercial execution, strategic business development, and disciplined capital deployment."

"Net revenue and adjusted EBITDA reached record highs this quarter, driven by strong performance from Jornay PM and our pain portfolio. Net revenue grew 31% year-over-year, while adjusted EBITDA increased 27% over the same period. We also generated meaningful operating cash flows, further strengthening our financial position," said Colleen Tupper, Chief Financial Officer. "We continue to execute our capital deployment strategy which balances rapidly paying down debt, opportunistically repurchasing shares, and actively evaluating opportunities to expand our portfolio through business development. We are on track to achieve our updated guidance, setting a solid foundation for continued growth in 2026."

**ADHD Business Highlights**

● Grew Jornay PM prescriptions 20% year-over-year in the quarter ended September 30, 2025 (the 2025 Quarter).

● Generated $41.8 million in Jornay PM net revenue in the 2025 Quarter. Full-year 2025 Jornay PM net revenue is expected to be in the range of $145 to $150 million.

● Jornay PM prescribers reached an all-time high in the 2025 Quarter with 27,700 healthcare providers writing Jornay PM prescriptions, up 22% year-over-year.

● In October, presented two posters at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute conferences highlighting real-world Jornay PM data.

**Pain Portfolio Highlights**

● Grew net revenues from pain portfolio to a record $167.6 million in the 2025 Quarter, up 11% year-over-year.

● Generated Belbuca <sup>®</sup> net revenue of $58.3 million in the 2025 Quarter, up 10% year-over-year.

● Generated Xtampza <sup>®</sup> ER net revenue of $50.5 million, up 2% year-over-year.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● Generated Nucynta Franchise net revenue of $54.8 million, up 21% year-over-year.

● In July and August, issued two publications in *Pain Research and Management* and *Journal of Pain Research* highlighting real-world benefits of treatment with Belbuca and Xtampza ER, respectively.

● In September, presented nine posters at PAINWeek 2025 showcasing real-world data from our pain portfolio.

**Corporate Updates**

● In July, our Board of Directors authorized a new share repurchase program to repurchase up to $150 million of common stock through December 31, 2026.

● In July, completed an accelerated share repurchase program returning $25 million of value to shareholders through the repurchase of 0.8 million shares at an average share price of $30.41.

● In October, management rang the Nasdaq opening bell in celebration of Collegium's 10-year anniversary as a publicly traded company on the Nasdaq Stock Market.

**Upcoming Events**

The Company will participate in the following upcoming investor conferences in the fourth quarter of 2025:

● Jefferies London Healthcare Conference – London, UK; November 19, 2025

● Piper Sandler 37th Annual Healthcare Conference – New York, NY; December 2, 2025

● Evercore 8th Annual Healthcare Conference – Coral Gables, FL; December 4, 2025

**Financial Guidance for 2025**

The Company updates its full-year 2025 guidance for Product Revenues, Net, Adjusted Operating Expenses, and Adjusted EBITDA:

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**Prior** | &nbsp;&nbsp;**Updated** |
| &nbsp;&nbsp;Product Revenues, Net | &nbsp;&nbsp;$745 - $760 million | &nbsp;&nbsp;$775 - $785 million |
| &nbsp;&nbsp;Jornay PM Revenues, Net | &nbsp;&nbsp;$140 - $145 million | &nbsp;&nbsp;$145 - $150 million |
| &nbsp;&nbsp;Adjusted Operating Expenses<br>(Excluding Stock-Based Compensation) | &nbsp;&nbsp;$225 - $235 million | &nbsp;&nbsp;$235 - $240 million |
| &nbsp;&nbsp;Adjusted EBITDA<br>(Excluding Stock-Based Compensation) | &nbsp;&nbsp;$440 - $455 million | &nbsp;&nbsp;$460 - $470 million |

---

**Financial Results for Quarter Ended September 30, 2025**

● Product revenues, net were $209.4 million for the 2025 Quarter, compared to $159.3 million for the quarter ended September 30, 2024 (the 2024 Quarter), representing a 31% increase year-over-year.

● GAAP operating expenses were $67.1 million for the 2025 Quarter, compared to $62.0 million for the 2024 Quarter, representing an 8% increase year-over-year. Adjusted operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were $55.7 million for the 2025 Quarter, compared to $34.8 million for the 2024 Quarter, representing a 60% increase year-over-year.

● GAAP net income for the 2025 Quarter was $31.5 million, with $1.00 GAAP earnings per share (basic) and $0.84 GAAP earnings per share (diluted), compared to GAAP net income for the 2024 Quarter of $9.3 million, with $0.29 GAAP earnings per share (basic) and $0.27 GAAP earnings per share (diluted). Non-GAAP

------

adjusted net income for the 2025 Quarter was $87.3 million, with $2.25 adjusted earnings per share, compared to non-GAAP adjusted net income for the 2024 Quarter of $63.5 million, with $1.61 adjusted earnings per share.

● Adjusted EBITDA for the 2025 Quarter was $133.0 million, compared to $105.1 million for the 2024 Quarter, representing a 27% increase year-over-year. The Company generated $78.4 million in cash from operations, and exited the 2025 Quarter with cash, cash equivalents and marketable securities of $285.9 million.

**Conference Call Information** 

The Company will host a conference call and live audio webcast on Thursday, November 6, 2025, at 8:00 a.m. ET. To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Third Quarter 2025 Earnings Call." An audio webcast will be accessible from the Investors section of the Company's website: www.collegiumpharma.com. The webcast will be available for replay on the Company's website approximately two hours after the event.

**About Collegium Pharmaceutical, Inc.**

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM<sup>®</sup>, a differentiated treatment for ADHD. Collegium's strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium's headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company's website at www.collegiumpharma.com.

**Non-GAAP Financial Measures** 

To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting. In addition, certain non-GAAP financial measures, primarily adjusted EBITDA, are used to measure performance when determining components of annual compensation for substantially all non-sales force employees, including senior management.

We may discuss the following financial measures that are not calculated in accordance with GAAP in our quarterly and annual reports, earnings press releases, and conference calls.

*Adjusted EBITDA*

Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as:

● adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;

● adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;

● adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes;

● adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;

● we exclude impairment expenses from adjusted EBITDA and, although these are non-cash expenses, the asset(s) being impaired may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;

● we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business;

● we exclude litigation settlements and contingencies that are subject to recovery from adjusted EBITDA, as well as any applicable income items or, credit adjustments, or recoveries due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred;

● we exclude acquisition related expenses as the amount and/or frequency of these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after the acquisition, legal defense expenses for specific acquired claims that relate to acts that occurred prior to our acquisition, and miscellaneous other acquisition related expenses incurred;

● we exclude recognition of the step-up basis in inventory from acquisitions (i.e., the adjustment to record inventory from historic cost to fair value at acquisition) as the adjustment does not reflect the ongoing expense associated with sale of our products as part of our underlying business;

● we exclude losses on extinguishments of debt as these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis;

● we exclude executive transition expenses from adjusted EBITDA as the amount and/or frequency of these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; and

● we exclude other expenses, from time to time, that are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis.

*Adjusted Operating Expenses*

Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations.

*Adjusted Net Income and Adjusted Earnings Per Share*

Adjusted net income is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude significant income and expense items that are non-cash or not indicative of ongoing operations, including consideration of the tax effect of the adjustments. Adjusted earnings per share is a non-GAAP financial measure that represents adjusted net income per share. Adjusted weighted-average shares - diluted is calculated in accordance with the treasury stock, if-converted, or contingently issuable accounting methods, depending on the nature of the security.

Reconciliations of adjusted EBITDA, adjusted operating expenses, adjusted net income, and adjusted earnings per share to the most directly comparable GAAP financial measures are included in this press release.

The Company has not provided a reconciliation of its full-year 2025 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expense and litigation settlements. These items are uncertain and depend on various factors that are outside of the Company's control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period. A reconciliation of adjusted EBITDA or adjusted

------

operating expenses would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our 2025 financial guidance, including projected product revenues, adjusted operating expenses and adjusted EBITDA, statements related to current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

**Investor Contacts:**<br> Ian Karp

Head of Investor Relations

ir@collegiumpharma.com

Danielle Jesse<br>Director, Investor Relations<br>ir@collegiumpharma.com

**Media Contact:**<br> Cheryl Wheeler

Head of Corporate Communications<br>communications@collegiumpharma.com

------

**Collegium Pharmaceutical, Inc.**

**Unaudited Selected Consolidated Balance Sheet Information**

(in thousands)

---

| | | |
|:---|:---|:---|
|  | **September 30,**<br>**2025** | **December 31,**<br>**2024** |
| Cash and cash equivalents | $150096 | $70565 |
| Marketable securities | 135767 | 92198 |
| Accounts receivable, net | 233949 | 228540 |
| Inventory | 38052 | 35560 |
| Prepaid expenses and other current assets | 36156 | 30394 |
| Property and equipment, net | 12249 | 14329 |
| Operating lease assets | 4432 | 5822 |
| Intangible assets, net | 724983 | 891402 |
| Restricted cash | 20904 | 26047 |
| Deferred tax assets | 102477 | 98033 |
| Other noncurrent assets | 2338 | 8368 |
| Goodwill | 145925 | 162333 |
| Total assets | $1607328 | $1663591 |
| Accounts payable and accrued liabilities | 59115 | 76058 |
| Accrued rebates, returns and discounts | 309608 | 338642 |
| Business combination consideration payable | 17565 | 28956 |
| Term notes payable | 570166 | 615316 |
| Convertible senior notes | 237950 | 237172 |
| Operating lease liabilities | 5873 | 6810 |
| Deferred royalty obligation | 122279 | 120613 |
| Deferred revenue | 9945 | 10000 |
| Contingent consideration | 19 | 1182 |
| Shareholders' equity | 274808 | 228842 |
| Total liabilities and shareholders' equity | $1607328 | $1663591 |

---

------

**Collegium Pharmaceutical, Inc.**

**Unaudited Condensed Statements of Operations**

(in thousands, except share and per share amounts)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Product revenues, net | $209361 | $159301 | $575118 | $449500 |
| Cost of product revenues |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product revenues (excluding intangible asset amortization) | 24717 | 21706 | 73820 | 60611 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible asset amortization | 55473 | 40801 | 166419 | 109833 |
| Total cost of product revenues | 80190 | 62507 | 240239 | 170444 |
| Gross profit | 129171 | 96794 | 334879 | 279056 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 67103 | 61955 | 217163 | 147272 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on fair value remeasurement of contingent consideration | (19) |  | (1163) |  |
| Total operating expenses | 67084 | 61955 | 216000 | 147272 |
| Income from operations | 62087 | 34839 | 118879 | 131784 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (21767) | (18394) | (63020) | (51320) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 3116 | 3280 | 7724 | 12164 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt |  | (4145) |  | (11329) |
| Income before income taxes | 43436 | 15580 | 63583 | 81299 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 11929 | 6245 | 17676 | 24645 |
| Net income | $31507 | $9335 | $45907 | $56654 |
| Earnings per share — basic | $1.00 | $0.29 | $1.45 | $1.75 |
| Weighted-average shares — basic | 31571410 | 32259468 | 31724439 | 32339401 |
| Earnings per share — diluted | $0.84 | $0.27 | $1.28 | $1.51 |
| Weighted-average shares — diluted | 39439890 | 40163266 | 39386071 | 40400483 |

---

------

**Collegium Pharmaceutical, Inc.**

**Reconciliation of GAAP Net Income to Adjusted EBITDA**

(in thousands)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| GAAP net income | $31507 | $9335 | $45907 | $56654 |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;Interest expense | 21767 | 18394 | 63020 | 51320 |
| &nbsp;&nbsp;Interest income | (3116) | (3280) | (7724) | (12164) |
| &nbsp;&nbsp;Loss on extinguishment of debt |  | 4145 |  | 11329 |
| &nbsp;&nbsp;Provision for income taxes | 11929 | 6245 | 17676 | 24645 |
| &nbsp;&nbsp;Depreciation | 1033 | 946 | 3259 | 2815 |
| &nbsp;&nbsp;Amortization | 55473 | 40801 | 166419 | 109833 |
| &nbsp;&nbsp;Stock-based compensation | 9811 | 7317 | 32153 | 24804 |
| &nbsp;&nbsp;Litigation settlements and contingencies | 3058 |  | 3058 |  |
| &nbsp;&nbsp;Recognition of step-up basis in inventory |  | 1301 | 5431 | 1301 |
| &nbsp;&nbsp;Executive transition expense |  |  | 1397 | 3051 |
| &nbsp;&nbsp;Acquisition related expenses | 1552 | 19886 | 3776 | 19886 |
| &nbsp;&nbsp;Gain on fair value remeasurement of contingent consideration | (19) |  | (1163) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total adjustments | $101488 | $95755 | $287302 | $236820 |
| Adjusted EBITDA | $132995 | $105090 | $333209 | $293474 |

---

------

**Collegium Pharmaceutical, Inc.**

**Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses**

(in thousands)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| GAAP operating expenses | $67084 | $61955 | $216000 | $147272 |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;Stock-based compensation | 9811 | 7317 | 32153 | 24804 |
| &nbsp;&nbsp;Executive transition expense |  |  | 1397 | 3051 |
| &nbsp;&nbsp;Acquisition related expenses | 1552 | 19886 | 3776 | 19886 |
| &nbsp;&nbsp;Gain on fair value remeasurement of contingent consideration | (19) |  | (1163) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total adjustments | $11344 | $27203 | $36163 | $47741 |
| Adjusted operating expenses | $55740 | $34752 | $179837 | $99531 |

---

------

**Collegium Pharmaceutical, Inc.**

**Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share**

(in thousands, except share and per share amounts)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| GAAP net income | $31507 | $9335 | $45907 | $56654 |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;Non-cash interest expense | 1343 | 1681 | 4065 | 5065 |
| &nbsp;&nbsp;Loss on extinguishment of debt |  | 4145 |  | 11329 |
| &nbsp;&nbsp;Amortization | 55473 | 40801 | 166419 | 109833 |
| &nbsp;&nbsp;Stock-based compensation | 9811 | 7317 | 32153 | 24804 |
| &nbsp;&nbsp;Litigation settlements and contingencies | 3058 |  | 3058 |  |
| &nbsp;&nbsp;Recognition of step-up basis in inventory |  | 1301 | 5431 | 1301 |
| &nbsp;&nbsp;Executive transition expense |  |  | 1397 | 3051 |
| &nbsp;&nbsp;Acquisition related expenses | 1552 | 19886 | 3776 | 19886 |
| &nbsp;&nbsp;Gain on fair value remeasurement of contingent consideration | (19) |  | (1163) |  |
| &nbsp;&nbsp;Income tax effect of above adjustments <sup>(1)</sup> | (15453) | (20974) | (52061) | (45635) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total adjustments | $55765 | $54157 | $163075 | $129634 |
| Non-GAAP adjusted net income | $87272 | $63492 | $208982 | $186288 |
| Adjusted weighted-average shares — diluted <sup>(2)</sup> | 39439890 | 40163266 | 39386071 | 40400483 |
| Adjusted earnings per share <sup>(2)</sup> | $2.25 | $1.61 | $5.41 | $4.71 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax effect. The blended federal and state statutory rate for the three months ended September 30, 2025 and 2024 were 21.8% and 28.1%, respectively; and the blended federal and state statutory rate for the nine months ended September 30, 2025 and 2024 were 24.5% and 27.1%, respectively. As such, the non-GAAP effective tax rates for the three months ended September 30, 2025 and 2024 were 21.7% and 27.9%, respectively; and the non-GAAP effective tax rates for the nine months ended September 30, 2025 and 2024 were 24.2% and 26.0%, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Adjusted weighted-average shares - diluted were calculated using the "if-converted" method for our convertible notes in accordance with ASC 260, *Earnings per Share*. As such, adjusted weighted-average shares – diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense is added-back to non-GAAP adjusted net income. For the three and nine months ended September 30, 2025 and 2024, adjusted weighted-average shares – diluted includes 6,606,305 shares attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive.

------

## Exhibit 99.2

#### Exhibit 99.2

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Q3 2025 Earnings Report November 6, 2025 \| Nasdaq: COLL Healthier people. Stronger communities. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this presentation include, among others, statements related to our full-year 2025 financial guidance, including projected product revenue, adjusted operating expenses and adjusted EBITDA, current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this presentation speak only as of the date of this presentation. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this presentation. Non-GAAP Financial Measures To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting. In addition, certain non-GAAP financial measures, primarily Adjusted EBITDA, are used to measure performance when determining components of annual compensation for substantially all non-sales force employees, including senior management. In this presentation, we discuss the following financial measures that are not calculated in accordance with GAAP, to supplement our consolidated financial statements presented on a GAAP basis. Adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as: • adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA; • adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs; • adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes; • adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments; • we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position; • we exclude impairment expenses from adjusted EBITDA and, although these are non-cash expenses, the asset(s) being impaired may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA; • we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business; • we exclude litigation settlements and contingencies that are subject to recovery from adjusted EBITDA, as well as any applicable income items, credit adjustments, or recoveries due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred; • we exclude acquisition related expenses as the amount and/or frequency of these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after the acquisition, legal defense expenses for specific acquired claims that relate to acts that occurred prior to our acquisition, and miscellaneous other acquisition related expenses incurred; • we exclude recognition of the step-up basis in inventory from acquisitions (i.e., the adjustment to record inventory from historic cost to fair value at acquisition) as the adjustment does not reflect the ongoing expense associated with sale of our products as part of our underlying business; • we exclude losses on extinguishments of debt as these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; • we exclude executive transition expenses from adjusted EBITDA as the amount and/or frequency of these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; and • we exclude other expenses, from time to time, that are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis. Adjusted Operating Expenses Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted Net Income and Adjusted Earnings Per Share Adjusted net income is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude significant income and expense items that are non-cash or not indicative of ongoing operations, including consideration of the tax effect of the adjustments. Adjusted earnings per share is a non-GAAP financial measure that represents adjusted net income per share. Adjusted weighted-average shares - diluted is calculated in accordance with the treasury stock, if-converted, or contingently issuable accounting methods, depending on the nature of the security. Reconciliations of adjusted EBITDA and adjusted operating expenses to the most directly comparable GAAP financial measures are included in this presentation. The Company has not provided a reconciliation of its full-year 2025 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expense and litigation settlements. These items are uncertain and depend on various factors that are outside of the Company's control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period. A reconciliation of adjusted EBITDA or adjusted operating expenses would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g003.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business Update Vikram Karnani President & Chief Executive Officer |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g004.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 Building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions Healthier people. Stronger communities. Collegium is Well-Positioned for Continued Growth 1. This financial data is calculated based on data provided by Collegium in its press release on Form 8-K filed with the SEC on November 6, 2025, and on February 27, 2025. 2025 guidance represents the mid-point of 2025 financial guidance ranges and estimated year-over-year change represents the mid-point of 2025 financial guidance ranges compared to 2024 financial results. Strong track record of using cash generated to fuel highly successful business development opportunities Committed to increasing shareholder value by growing revenues, adjusted EBITDA and strategically deploying capital $631M $780M +24% FIVE MARKETED PRODUCTS1 2024 sales 2025 expected sales  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g005.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 Recent Business Highlights – Q3 20251 1. Unless otherwise noted, this financial data was provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025. 2. IQVIA NPA through September 2025. 3. Represents a non-GAAP financial measure. Refer to "Non-GAAP Financial Measures" on slide 2. 4. Net debt/adjusted EBITDA is calculated based on financial data provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025. Accelerated Commercial Momentum +20% YoY growth in Q3'25 prescriptions2 +11% YoY growth in Q3'25 net revenue Pain Portfolio Strategically Deployed Capital and Strengthened Balance Sheet $78.4M in cash from operations; $285.9M in cash, cash equivalents, and marketable securities, up $123.1M from December 2024 ~1.2x net debt to adjusted EBITDA at end of Q3'253,4 $25M Accelerated Share Repurchase completed in July 2025 $150M share repurchase program authorized through December 2026 Achieved Top-and Bottom-line Growth Product Revenues, Net $159.3M Q3'24 $209.4M Q3'25 $105.1M Q3'24 $133.0M Q3'25 +31% +27% Adjusted EBITDA3 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g006.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DRIVE SIGNIFICANT Jornay PM Growth • Invest in Jornay PM to support near-term growth and create significant momentum in 2026 and beyond • Increase adoption in an expanded set of prescribers • Raise awareness in patients and caregivers to drive prescription growth 6 Building on a Successful Strategy STRATEGICALLY Deploy Capital • Expand portfolio through disciplined business development • Rapidly pay down debt and opportunistically repurchase shares MAXIMIZE Pain Portfolio • Maximize and enhance durability of pain portfolio • Generate durable operating cash flows from portfolio of differentiated medicines |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g007.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 Collegium's Vision for the Next Phase of Growth1 Time 1. Illustrative purposes only. Opportunity FUTURE FURTHER EXPANSION Product diversification and capital deployment NEUROPSYCHIATRY PAIN PORTFOLIO |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g008.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial Update Scott Dreyer Executive Vice President & Chief Commercial Officer |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g009.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Strong Intent to Increase Prescribing 9 Product Differentiation and Strong Brand Fundamentals Drive Utilization1 1. ATU (Awareness, Trial, & Usage) Market Research Study, completed Q2 2025. Jornay PM Considered Highly Differentiated #1 highest rated branded ADHD medicine in terms of product differentiation >60% of surveyed HCPs plan to increase prescribing (highest among all other branded ADHD medicines) >70% of patients/caregivers who request Jornay PM from their physician, receive it |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g010.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Q3'24 Q3'25 Q3'24 Q3'25 10 Fastest Growing Stimulant for Treatment of ADHD STRONG AND GROWING PRESCRIBER BASE2 GROWTH IN QUARTERLY PRESCRIPTIONS1 1. IQVIA NPA through September 2025. 2. IQVIA Xponent through September 2025; approximate quarterly prescriber counts. MARKET SHARE IN BRANDED LONG-ACTING METHYLPHENIDATE MARKET1 Q3'24 Q3'25 +20% +22% GROWTH IN AVERAGE WEEKLY PRESCRIPTIONS DURING "BACK-TO-SCHOOL" SEASON1 July '25 October '25 +14% 160K 192K 23K 28K 17% 23% 14K 16K +6 Percentage Points |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g011.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 Investing in Jornay PM to Drive Additional Momentum Increase Awareness and Adoption with Expanded Set of Prescribers • Expanded ADHD sales force to ~180 sales reps deployed to cover full market opportunity • Leveraging non-personal promotion to increase awareness and use Raise Caregiver and Patient Awareness to Drive HCP Request • Launched digital marketing and social media strategies to target caregivers and patients for "back-to-school" season • Announced a new collaboration with entrepreneur, musician, author, and advocate, Paris Hilton • Developed and launched new patient support resources $100.7M2 $145 -150M 2024 2025E JORNAY PM NEAR-TERM REVENUE EXPECTATIONS1 COMMERCIAL PRIORITIES FOCUSED ON GROWTH 2025 investments in Jornay PM expected to support near-term growth and drive significant momentum in 2026 and beyond +46% 1. This financial data is calculated based on data provided by Collegium in its press release on Form 8-K filed with the SEC on November 6, 2025, and on February 27, 2025. The estimated year-over-year change represents the mid-point of 2025 financial guidance ranges compared to 2024 financial results. 2. Represents pro forma Jornay PM net revenue. Collegium recognized $37.2M of Jornay PM net revenue in 2024 following the close of the Ironshore Therapeutics acquisition on September 3, 2024. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g012.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12 Well Positioned to Maximize and Enhance Durability of Responsible Pain Management Portfolio 1. This financial data was provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025. 2. ATU (Awareness, Trial, & Usage) Market Research Study, fielded Q4 2022. #1 highest rated branded ER opioid in terms of product differentiation and favorability 74% of surveyed target HCPs plan to increase prescribing STRONG BRAND FUNDAMENTALS2 #1 highest rated ER oxycodone in terms of product differentiation and favorability 48% of surveyed target HCPs plan to increase prescribing SUCCESSFUL COMMERCIAL EXECUTION OF GROWTH STRATEGY1 $50.5M +2% YoY growth in Q3'25 revenues $58.3M +10% YoY growth in Q3'25 revenues |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g013.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Highlights Colleen Tupper Executive Vice President & Chief Financial Officer |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g014.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$105.1M $133.0M Q3'24 Q3'25 Q3'25 Financial Highlights1 Record Product Revenues, Net $159.3M $209.4M Q3'24 Q3'25 +31% Adjusted Operating Expenses2 $34.8M $55.7M Q3'24 Q3'25 +60% Record Adjusted EBITDA2 +27% 14 1. This financial data was provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025. 2. Represents a non-GAAP financial measure. Refer to "Non-GAAP Financial Measures" on slide 2. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g015.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Raised 2025 Financial Guidance 1. Represents a non-GAAP financial measure. Refer to "Non-GAAP Financial Measures" on slide 2. 2. This financial data was provided by Collegium in its press release on Form 8-K filed with the SEC on August 7, 2025. 3. This financial data is calculated based on data provided by Collegium in its press release on Form 8-K filed with the SEC on November 6, 2025, and on February 27, 2025. The estimated year-over-year change represents the mid-point of 2025 financial guidance ranges compared to 2024 financial results. 15 Prior Guidance Range2 Updated Guidance Range YoY Change3 Product Revenues, Net $745 – 760M $775 – 785M +24% Jornay PM Revenue, Net $140 - 145M $145 - 150M +46% Adjusted EBITDA1 $440 – 455M $460 – 470M +16% Adjusted Operating Expenses1 $225 – 235M $235 – 240M +58% |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g016.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disciplined Capital Deployment 16 1. This financial data was provided by Collegium in its Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025, and Annual Reports on Form 10-K filed with the SEC on February 22, 2024, and February 27, 2025. 2. Adjusted EBITDA is a non-GAAP financial measure. Refer to "Non-GAAP Financial Measures" on slide 2. Net debt/adjusted EBITDA is calculated based on financial data provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on November 6, 2025. Estimated 2025 net debt/adjusted EBITDA is calculated based on Collegium's forecast of net debt at year-end 2025, compared to the mid-point of the 2025 guidance ranges provided by Collegium in its press release filed with the SEC on November 6, 2025. This financial data assumes no additional debt is incurred. EXPAND PORTFOLIO THROUGH BUSINESS DEVELOPMENT • Acquisition of Ironshore added lead growth driver, Jornay PM, new sales force in neuropsychiatry & pediatrics, and new platform for growth in ADHD • Further expand and diversify portfolio through business development OPPORTUNISTICALLY LEVERAGE SHARE REPURCHASE PROGRAM • $25M Accelerated Share Repurchase completed in July 2025 • Repurchased $222M in shares since 20211 • $150M share repurchase program authorized by Board through December 2026 RAPIDLY PAY DOWN DEBT • Ended Q3'25 with net leverage of ~1.2x2 • Rapidly deleveraging and expect to end 2025 with net leverage of <1.0x2 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g017.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Closing Remarks Vikram Karnani President & Chief Executive Officer |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g018.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collegium's Next Phase of Growth 18 Growing Revenue CREATING VALUE FOR SHAREHOLDERS Increasing Profitability Generating Strong Cash Flows Strategically Deploying Capital Business Development |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g019.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 Healthier people. Stronger communities. Building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g020.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP Reconciliations |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g021.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21 Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands, unaudited) GAAP net income $31,507 $9,335 $45,907 $56,654 Adjustments: Interest expense 21,767 18,394 63,020 51,320 Interest income (3116) (3280) (7724) (12164) Loss on extinguishment of debt — 4,145 — 11,329 Provision for income taxes 11,929 6,245 17,676 24,645 Depreciation 1,033 946 3,259 2,815 Amortization 55,473 40,801 166,419 109,833 Stock-based compensation 9,811 7,317 32,153 24,804 Litigation settlements and contingencies 3,058 — 3,058 — Recognition of step-up basis in inventory — 1,301 5,431 1,301 Executive transition expense — — 1,397 3,051 Acquisition related expenses 1,552 19,886 3,776 19,886 Gain on fair value remeasurement of contingent consideration (19) — (1163) — Total adjustments $101,488 $95,755 $287,302 $236,820 Adjusted EBITDA $132,995 $105,090 $333,209 $293,474 2025 Three Months Ended September 30, 2024 Nine Months Ended September 30, 2025 2024 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g022.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22 Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands, unaudited) GAAP operating expenses $67,084 $61,955 $216,000 $147,272 Adjustments: Stock-based compensation 9,811 7,317 32,153 24,804 Executive transition expense — — 1,397 3,051 Acquisition related expenses 1,552 19,886 3,776 19,886 Gain on fair value remeasurement of contingent consideration (19) — (1163) — Total adjustments $11,344 $27,203 $36,163 $47,741 Adjusted operating expenses $55,740 $34,752 $179,837 $99,531 2025 2024 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](coll-20251106xex99d2g023.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23 Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share (in thousands, except share and per share amounts, unaudited) 1. The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax effect. The blended federal and state statutory rate for the three months ended September 30, 2025 and 2024 were 21.8% and 28.1%, respectively; and the blended federal and state statutory rate for the nine months ended September 30, 2025 and 2024 were 24.5% and 27.1%, respectively. As such, the non-GAAP effective tax rates for the three months ended September 30, 2025 and 2024 were 21.7% and 27.9%, respectively; and the non-GAAP effective tax rates for the nine months ended September 30, 2025 and 2024 were 24.2% and 26.0%, respectively. 2. Adjusted weighted-average shares - diluted were calculated using the "if-converted" method for our convertible notes in accordance with ASC 260, Earnings per Share. As such, adjusted weighted-average shares – diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense is added-back to non-GAAP adjusted net income. For the three and nine months ended September 30, 2025 and 2024, adjusted weighted-average shares – diluted includes 6,606,305 shares attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive. GAAP net income $31,507 $9,335 $45,907 $56,654 Adjustments: Non-cash interest expense 1,343 1,681 4,065 5,065 Loss on extinguishment of debt — 4,145 — 11,329 Amortization 55,473 40,801 166,419 109,833 Stock-based compensation 9,811 7,317 32,153 24,804 Litigation settlements and contingencies 3,058 — 3,058 — Recognition of step-up basis in inventory — 1,301 5,431 1,301 Executive transition expense — — 1,397 3,051 Acquisition related expenses 1,552 19,886 3,776 19,886 Gain on fair value remeasurement of contingent consideration (19) — (1163) — Income tax effect of above adjustments (1) (15453) (20974) (52061) (45635) Total adjustments $55,765 $54,157 $163,075 $129,634 Non-GAAP adjusted net income $87,272 $63,492 $208,982 $186,288 Adjusted weighted-average shares — diluted (2) 39,439,890 40,163,266 39,386,071 40,400,483 Adjusted earnings per share (2) $2.25 $1.61 $5.41 $4.71 Three Months Ended September 30, 2025 2024 Nine Months Ended September 30, 2025 2024 |

---